glp-1 receptor agonists blindness risk Eye doctors warn drugs for diabetes and weight loss may pose rare vision risks, recommending regular checkups Full article: Glucagon-Like Peptide-1 Analogs

However, plasma concentrations of semaglutide at steady state are estimated to be about 100 times lower than the IC 50 values for OATP1B1/3 (3.50 M and 2.95 M, respectively).56 Moreover, when BSA was added, the inhibitory effect disappeared or was diminished, probably due to the binding of the fatty acid residues of GLP-1 RAs and a dual GLP-1/GIP RA to BSA.70 Table 3

Companies like Novo Nordisk and Eli Lilly and Company are pushing the boundaries of metabolic science with next generation GLP-1 and incretin based therapies

In the same trial, tirzepatide and semaglutide were compared once weekly in the open-label, phase III SURPASS-2 experiment

Resistin is a key mediator of glucosedependent insulinotropic polypeptide (GIP) stimulation of lipoprotein lipase (LPL) activity in adipocytes